Compression hosiery to avoid post-thrombotic syndrome (CHAPS) protocol for a randomised controlled trial (ISRCTN73041168)

Ankur Thapar, Rebecca Lawton, Laura Burgess, Joseph Shalhoub, Andrew Bradbury, Nicky Cullum, David Epstein, Manjit Gohel, Robert Horne, Beverley J Hunt, John Norrie, A H Davies

ABSTRACT

Introduction Up to 50% of patients develop post-thrombotic syndrome (PTS) after an above knee deep vein thrombosis (DVT). The aim of the study was to determine the effect of graduated compression stockings in preventing PTS after DVT.

Methods and analysis Pragmatic, UK multicentre randomised trial in adults with first above knee DVT. The standard of care arm is anticoagulation. The intervention arm will receive anticoagulation plus stockings (European class II, 23–32 mm Hg compression) worn for a median of 18 months. The primary endpoint is PTS using the Villalta score. Analysis of this will be through a time to event approach and cumulative incidence at median 6, 12 and 18 months. An ongoing process evaluation will examine factors contributing to adherence to stockings to understand if and how the behavioural interventions were effective.

Ethics and dissemination UK research ethics committee approval (reference 19/LO/1585). Dissemination through the charity Thrombosis UK, the Imperial College London website, peer-reviewed publications and international conferences.

Trial registration number ISRCTN registration number 73041168.

INTRODUCTION

Deep vein thrombosis (DVT) occurs in 1–2 per 1000 adults in the UK and half will go on to develop lifelong disability from post-thrombotic syndrome (PTS). PTS is defined as ‘chronic venous symptoms or signs secondary to deep vein thrombosis’ for example, leg pain, oedema and skin changes, progressing in 5% to ulceration. The average age of patients developing PTS is 55 years, meaning that most are of working age. Individuals with PTS have difficulty walking and therefore maintaining employment, and have a level of disability comparable to chronic obstructive pulmonary disease. The pathophysiology of PTS is sustained venous hypertension from venous outflow obstruction and valvar incompetence.

The recent negative results of the ATTRACT trial have focussed attention on the effectiveness of graduated compression stockings (GCS) in preventing PTS. The UK National Institute for Health and Care Excellence (NICE) and the American College of Chest Physicians recently withdrew their recommendations for the use of GCS in the prevention of PTS based on the results of the SOX trial. However, European guidelines still recommend stockings.

A recent systematic review examined randomised controlled trials (RCTs) in this area. Three RCTs inclusive of 1177 patients examined the use of GCS providing 30–40 mm Hg compression at the ankle versus either no stocking, or a placebo. Follow-up ranged from 2 to 5 years with a primary outcome measure of cumulative incidence of PTS. There was important clinical, methodological and statistical heterogeneity between trials (I²=94%). Key clinical differences were variable inclusion of patients with chronic venous disease, variable baseline rates of PTS and differing anatomy of DVT. Key methodological differences were the use of a placebo stocking versus a no stocking control arm.
and differing PTS scoring systems. Additionally, adherence varied between 56% and 93%.

The largest placebo-controlled trial showed no difference in the outcome of PTS with the use of stockings. The other two assessor blind trials showed absolute risk reductions of 23% and 39% with the use of stockings. There appeared to be more benefit from the use of GCS in populations with a higher baseline risk of PTS. Compression hosiery to avoid post-thrombotic syndrome (CHAPS) is a multicentre, pragmatic, assessor-blind, RCT of adults with a first above knee DVT, comparing the regular use of a stocking with no stocking in preventing PTS.

PTS comprises a substantial economic burden on health systems, patients and society due to days lost to illness. The cost of three pairs of high-quality GCS per year is around £150, but this expense may be offset to some extent by lower costs elsewhere. Under standard care, around 50% of DVTs result in PTS. Given the high cost of treatment of PTS, especially venous ulcers and the impact on quality of life, the addition of GCS could be a cost-effective addition to standard treatment.

METHODS AND ANALYSIS
CHAPS is a multicentre, pragmatic, assessor-blind superiority RCT. The trial will follow patients up for a median of 18 months (range 6–30 months). The study commenced on 1 May 2019 and is due to close on 31 January 2023. Please see figure 1 for a Consolidated Standards of Reporting Trials diagram and online supplemental appendix 1 for a Standard Protocol Items: Recommendations for Interventional Trials checklist.

Eligibility
Table 1 details inclusion and exclusion criteria. Peripheral arterial disease will be screened for using pedal pulse palpation, with ankle brachial pressure index where equivocal.

Recruitment
Recruitment will be from emergency departments, ambulatory care, DVT, vascular, obstetric or haematology clinics in 11 UK hospitals (see www.ISCTRN.com for details), via the National Institute for Health Research (NIHR) Clinical Research Network and trial nurses. Recruitment of 864 participants is planned over 24 months from both academic and non-academic centres. Informed consent will be obtained in writing (online supplemental appendix 2) by the local study nurse.

Study arms
Standard care
Anticoagulation for a minimum of 3 months (as per NICE recommendations8). The type and duration of anticoagulation beyond 3 months will be determined by local guidelines with the expectation that this will be a direct oral anticoagulant for the majority. A placebo stocking arm was not included because of ease of breaking blinding. GCS are not be recommended for treatment of acute leg pain.17

Intervention arm
Anticoagulation plus a standardised below knee compression stocking (European class II, 23–32mm Hg compression) worn during waking hours until the end of the trial, or until an alternative is required, for example, compression bandaging for venous ulceration. Minor variations such as change in fabric, open or closed toe or thigh length stockings are permissible if they aid adherence.

A number of behavioural aids will be made available to patients in the stocking arm:
► Patient education video at baseline
► Patient and carer refresher session for stocking donning and doffing within 2 weeks
► Free provision of a donning aid if required
► Cotton stocking for summer use

The following participant retention strategies have been employed:
► Travel cost reimbursement
► Weekly text message reminders to wear stockings
► A Facebook support group for stocking wearers
► Next of kin contact for follow-up

Stockings will be fitted and issued by a local research nurse at first visit. Within 2 weeks, there will be a face-to-face or video call refresher session for donning and doffing with the research nurse, patient and carer.

Randomisation
Participants will undergo 1:1 web-based randomisation by a local research nurse using the Research Electronic Data Capture (REDCap) database hosted at the Edinburgh Clinical Trials Unit.

Primary effectiveness endpoint
The primary outcome measure is PTS as assessed by the recommended Villalta score at a median of 18 months follow-up. This will be supplemented by a time to onset of PTS model.

Secondary endpoints
1. Venous ulceration
2. Employment status (change in number of days working from baseline)
3. Quality of life measured using VEINES (Venous Insufficiency Epidemiological and Economic Study)-QoL and EuroQoL EQ5D scales
4. Adherence to stockings and anticoagulants
5. Cost-effectiveness of stocking prescription

Sample size
The sample size calculation for CHAPS was based on the cumulative incidence of PTS at 18 months in the recent SOX trial.4 A minimum clinically important difference of a 10% absolute risk reduction in PTS with GCS was chosen multifactorially, based on patient consultation, the degree of behaviour change required by patients and to be less than that found in earlier positive stocking trials (absolute
Figure 1 CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; NICE, National Institute for Health and Care Excellence. B-IPQ, Brief illness perception questionnaire; BSQ, Beliefs about stockings questionnaire; MARS, Medicine adherence rating scale; NICE CG 144, National Institute for Health and Clinical Excellence Clinical Guideline 144; Qol, Quality of life; TIQ, Treatment Intrusiveness Questionnaire; VEINS, Venous insufficiency epidemiological and economic study.
risk reduction 23%–39%), reflecting improvements in anticoagulation. With 864 participants randomised 1:1, the study will have 90% power at a 5% level of significance using a test of binomial proportions to detect an absolute reduction in the incidence of PTS from 30% in the standard care arm to 20% in the intervention arm, allowing for 10% loss to follow-up. This reduction would represent a number needed to treat of 10 to prevent one case of PTS.

**Internal pilot study**

An internal pilot study will follow a randomly selected group of 200 patients over the first 12 months, leading to a mixed-methods process evaluation of factors contributing to GCS adherence. Adaptations of the Medication Adherence Rating Scale (MARS), the Brief Illness Perception Questionnaire (B-IPQ), and a novel Beliefs about Stockings Questionnaire (BSQ) will be given to participants at the 1 month, 6 and 12 months and final follow-up assessments. Qualitative interviews from a purposive sample of 20 patients at 1 month and 7 months will be used to examine factors affecting GCS adherence in further depth.

**Trial stopping criteria**

A combination of self-reported adherence and stocking reordering behaviour will be used to adjudicate adherence at the end of the pilot. The criteria for adequate 1-year adherence is ≥70% of participants in the intervention arm wearing the stocking for ≥4 days per week, with a documented stocking reorder in the last 6 months. This is the remit of the Trial Steering Committee (TSC). If this is achieved, the trial will continue into the main study. If this is not achieved, the trial will terminate and a process evaluation of factors influencing adherence will be reported.

---

**Table 1** Eligibility criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic presentation of first deep vein thrombosis, &lt;2 weeks from diagnosis</td>
<td>Previously intolerant of or already wearing graduated compression stockings for more than 1 month</td>
</tr>
<tr>
<td>Imaging confirmed, lower limb deep vein thrombosis (popliteal, femoral, iliac or combination)</td>
<td>Contraindication to wearing graduated compression stockings or allergy to fabric</td>
</tr>
<tr>
<td>Ability to give informed consent</td>
<td>Life expectancy &lt;2 years</td>
</tr>
<tr>
<td>Age 18 years or over</td>
<td>Bilateral deep vein thrombosis</td>
</tr>
<tr>
<td></td>
<td>Previous chronic venous insufficiency (patients with existing chronic skin changes or ulceration, defined as C4,5,6 by CEAP classification)</td>
</tr>
<tr>
<td></td>
<td>Pre-existing post-thrombotic syndrome, significant leg pain (eg, knee arthritis, spinal claudication) or oedema (eg, lymphoedema)</td>
</tr>
<tr>
<td></td>
<td>Newly diagnosed cancer, metastatic cancer or cancer undergoing active treatment or palliation</td>
</tr>
<tr>
<td></td>
<td>Contraindication to anticoagulation</td>
</tr>
</tbody>
</table>

CEAP, Clinical, Etiological, Anatomical, Pathophysiological classification.

---

**Assessment of outcomes and of blinding**

The study is assessor blind. An independent researcher at each site will perform Villalta assessments blind to treatment allocation. Participants will remove their stockings on the night prior to their clinic visit and be instructed not to discuss stockings during their assessment. The following questionnaires will be administered at follow-up visits: EQ5D, VEINES-QoL and MARS. Employment status (average number of days per week currently working) and healthcare resource use (contacts and outcomes of interactions with health services) will also be collected. Data will be entered by the local research team onto the web-based database REDCap.

Blinding will be evaluated by asking assessors which arm they believe the participant is in. Unblinding is permissible only if a stocking-related significant adverse event is suspected.

**Data monitoring**

In line with NIHR recommendations, a Trial Steering Committee (TSC) and an independent Data Monitoring Committee have been appointed to oversee trial conduct (please see online supplemental appendix 3). A Trial Manager together with the TSC will oversee trial progress. The study will be monitored by the Edinburgh Clinical Trials Unit to assess the progress of the study, verify adherence to the protocol and Good Clinical Practice guidelines and to review the completeness, accuracy and consistency of the data, through the use of independent data monitors. Pseudoanonymised data will be stored on REDCap, with a local key held by site Principal Investigators (PIs) to link this to clinical patient records. Data will be filed for 10 years as per local policy and then deleted.

**Data analysis**

The primary analysis will be an intention-to-treat analysis that does not adjust for adherence to stockings. This will
be performed independently by the Edinburgh Clinical Trials Unit who will have sole access to the final REDCap data set. This will determine the treatment effect given the adherence in the trial, which is appropriate to gauge real-world effectiveness. The occurrence of PTS will be analysed in both a time-to-PTS approach (since it is possible that the treatment effect may both avert PTS, and also possibly delay its onset) and through analysis of cumulative incidence at a median of 6, 12 and 18 months (as recommended by the International Society for Thrombosis and Haemostasis and peer reviewers). Prespecified subgroup analyses including iliac vein involvement and body mass index >30 kg/m².

To determine the effect of optimum adherence (wearing a stocking for the trial duration for ≥4 days per week) on outcome, a secondary analysis will use Complier Average Causal Estimation modelling through instrumental variable regression. The results of the process evaluation will report which behavioural components change participants knowledge, beliefs and intentions regarding stocking usage. Participants who discontinue the study will have information until date of leaving available for analysis.

Health economic analysis
Resource arising from the trial interventions, visits and admissions to hospital, general practice visits, community nursing and social and personal care will be collected during follow ups at 6 months, 12 months and the final visit and supplemented by case note review.

Employment status (average number of days worked per week, along with days lost from work and normal activities) will be collected from patients by questionnaire at baseline and at 6 months, 12 months and final follow-up.

A within-trial analysis and a decision model will be constructed. In both cases, the main analyses will be performed from the perspective of the UK NHS and Personal Social Services at 2018/2019 prices. Secondary analyses will be performed from a societal perspective. The results of the analyses will be presented as estimates of mean incremental costs, effects, and, incremental cost per quality-adjusted life year. Sensitivity analyses will be conducted to test the robustness of the results to alternative assumptions about model structure, assumptions and input data. Probabilistic sensitivity analysis will be conducted using Monte-Carlo simulation.

Ethics and dissemination
The trial was granted ethical approval (National Research Ethics Service ref. 19/LO/1585).

Protocol amendments will be circulated by email to investigators and study nurses to cascade to participants. Dissemination of results will be by the CHAPS coinvestigators in peer-reviewed journals and international conferences and to a lay audience through the Thrombosis UK website.

Adverse events and liability
All treatment-related adverse events will be collected by site PIs. The chief investigator (CI) will be notified of all serious adverse events within 24 hours. All serious adverse events will be reported to the research ethics committee and sponsor, if, in the opinion of the CI, the event was related to the intervention. All related adverse events and serious adverse events will be recorded and summarised by treatment strategy. The sponsor (Imperial College London) holds a relevant insurance.

Patient and public involvement
Patients, their carers’ and relatives were involved in a three-stage consultation process during the trial development stage, incorporating NIHR INVOLVE methodology. This consisted of a series of semistructured interviews, a survey run via Thrombosis UK, and review of the CHAPS research plan and lay summary. Responses and feedback were incorporated into the design and budget of CHAPS. The Imperial Vascular PPI group has contributed four patients and two members of the public will advise the steering committee for the duration of the trial.

CONCLUSION
The NIHR funded CHAPS trial will examine whether class II GCs prevent PTS, are cost-effective and the factors influencing adherence at a median 18 months follow-up (range 6–30 months).

Author affiliations
1Academic Section of Vascular Surgery, Imperial College London, London, UK
2Faculty of Health Education, Medicine & Social Care, Anglia Ruskin University, Chelmsford, Essex, UK
3Vascular and Endovascular Surgery, Mid and South Essex Hospitals NHS Foundation Trust, Basildon, Essex, UK
4Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
5School of Nursing, Midwifery and Social Work, The University of Manchester, Manchester, UK
6Faculty of Economic and Business Sciences, University of Granada, Granada, Andalucia, Spain
7Department of Vascular Surgery, Addenbrooke’s Hospital, Cambridge, UK
8School of Pharmacy, University College London, London, London, UK
9Department of Haematology, Guy’s & St Thomas’ Foundation Trust, London, UK
10Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK

Contributors
AT, JS, NC, MG, BJH developed the protocol and drafted the manuscript. RL and LB developed the PPI section and drafted the manuscript. DE developed the health economic section and drafted the manuscript. RH developed the adherence substudy and drafted the manuscript. JL developed the manuscript, calculated the sample size calculation and constructed the data analysis plan. AHD is the overall project coordinator and drafted the manuscript.

Funding
This work was supported by the National Institute for Health Research (NIHR), Health Technology Assessment Programme, project number 17/147/74. The HTA Programme is funded by the NIHR, with contributions from the Chief Scientist Office in Scotland and National Institute for Social Care and Health Research in Wales and the Health and Social Care R&D Division, Public Health Agency in Northern Ireland. Sponsor: Imperial College London.

Disclaimer
The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR or the UK Department of Health and Social Care.

Competing interests
None declared.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those
REFERENCES

### SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Page</th>
<th>Item No</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Administrative information</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
</tr>
<tr>
<td>Trial registration</td>
<td>1</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>3</td>
<td>Date and version identifier</td>
</tr>
<tr>
<td>Funding</td>
<td>3</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>4</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
</tr>
<tr>
<td></td>
<td>App2</td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Background and rationale</td>
<td>7</td>
<td>6a</td>
<td>Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6b</td>
<td>Explanation for choice of comparators</td>
</tr>
<tr>
<td>Objectives</td>
<td>10</td>
<td>7</td>
<td>Specific objectives or hypotheses</td>
</tr>
<tr>
<td>Trial design</td>
<td>9</td>
<td>8</td>
<td>Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)</td>
</tr>
</tbody>
</table>
### Methods: Participants, interventions, and outcomes

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
<th>Page 9</th>
<th>Page 10</th>
<th>Page 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study setting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Description of study settings (e.g., community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained.</td>
<td>9</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (e.g., surgeons, psychotherapists)</td>
<td>9</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interventions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered</td>
<td>9</td>
<td>11a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Criteria for discontinuing or modifying allocated interventions for a given trial participant (e.g., drug dose change in response to harms, participant request, or improving/worsening disease)</td>
<td>9</td>
<td>11b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (e.g., drug tablet return, laboratory tests)</td>
<td>9</td>
<td>11c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relevant concomitant care and interventions that are permitted or prohibited during the trial</td>
<td>9</td>
<td>11d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary, secondary, and other outcomes, including the specific measurement variable (e.g., systolic blood pressure), analysis metric (e.g., change from baseline, final value, time to event), method of aggregation (e.g., median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended</td>
<td>10</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant timeline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)</td>
<td>15</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations</td>
<td>10</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strategies for achieving adequate participant enrolment to reach target sample size</td>
<td>9</td>
<td>15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Methods: Assignment of interventions (for controlled trials)

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
<th>Page 10</th>
<th>Page 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sequence generation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method of generating the allocation sequence (e.g., computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (e.g., blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions.</td>
<td>10</td>
<td>16a</td>
<td></td>
</tr>
</tbody>
</table>
Allocation concealment mechanism

Mechanism of implementing the allocation sequence (e.g., central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Implementation

Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions

Blinding (masking)

Who will be blinded after assignment to interventions (e.g., trial participants, care providers, outcome assessors, data analysts), and how

If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial

Methods: Data collection, management, and analysis

Data collection methods

Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (e.g., duplicate measurements, training of assessors) and a description of study instruments (e.g., questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

Data management

Plans for data entry, coding, security, and storage, including any related processes to promote data quality (e.g., double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol

Statistical methods

Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol

Methods for any additional analyses (e.g., subgroup and adjusted analyses)

Definition of analysis population relating to protocol non-adherence (e.g., as randomised analysis), and any statistical methods to handle missing data (e.g., multiple imputation)

Methods: Monitoring

Data monitoring

Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial.

Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct.

Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor.

**Ethics and dissemination**

<table>
<thead>
<tr>
<th>Research ethics approval</th>
<th>Protocol amendments</th>
<th>Consent or assent</th>
<th>Confidentiality</th>
<th>Declaration of interests</th>
<th>Access to data</th>
<th>Ancillary and post-trial care</th>
<th>Dissemination policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation</td>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions</td>
</tr>
</tbody>
</table>
### Appendices

<table>
<thead>
<tr>
<th>Informed consent materials</th>
<th>App1 32</th>
<th>Model consent form and other related documentation given to participants and authorised surrogates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biological specimens</td>
<td>n.a 33</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable</td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.*
### CHAPS Trial Committees

**Trial Steering Committee**

**Bold = independent member**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Peter</td>
<td>Senior Lecturer in Haematology</td>
</tr>
<tr>
<td>Dr Susie</td>
<td>Consultant Haematologist</td>
</tr>
<tr>
<td>Mr Isaac</td>
<td>Consultant Vascular Surgeon</td>
</tr>
<tr>
<td>Dr Stephen</td>
<td>Senior medical statistician and NIHR doctoral research fellow</td>
</tr>
<tr>
<td>Professor</td>
<td>Professor of Vascular Surgery</td>
</tr>
<tr>
<td>Mr Andrew</td>
<td>PPI member</td>
</tr>
<tr>
<td>Mr David</td>
<td>PPI member</td>
</tr>
<tr>
<td>Mr Ankur</td>
<td>Co-applicant</td>
</tr>
<tr>
<td>Professor</td>
<td>Senior Statistician</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information placed on this supplemental material which has been supplied by the author(s).

### Data monitoring committee

**Bold = independent member**

<table>
<thead>
<tr>
<th>Mr</th>
<th>Richard</th>
<th>Bulbulia</th>
<th>Consultant Vascular Surgeon</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr</td>
<td>Natalie</td>
<td>Staplin</td>
<td>Senior Statistician – Renal Studies Group</td>
<td>Member</td>
</tr>
<tr>
<td>Mr</td>
<td>Richard</td>
<td>Haynes</td>
<td>Associate Professor</td>
<td>Member</td>
</tr>
<tr>
<td>Mr</td>
<td>Keith</td>
<td>Poskitt</td>
<td>Consultant Vascular and General Surgeon</td>
<td>Member</td>
</tr>
<tr>
<td>Mr</td>
<td>Imad</td>
<td>Adamestam</td>
<td>Trial Statistician</td>
<td></td>
</tr>
</tbody>
</table>
Compression Hosiery to Avoid Post-Thrombotic Syndrome

(CHAPS)

ISRCTN: 73041168

HRA/REC Reference: 19/LO/1585

IRAS 263041

Sponsor Reference: 19CX5434

Acknowledgement

This project is funded by a National Institute for Health Research, Health Technology Assessment programme grant, which is funded by the National Institute for Health Research (NIHR)

Disclaimer

The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NHS, NIHR or the Department of Health.
Compression Hosiery to Avoid Post-thrombotic Syndrome (CHAPS)

IRAS 263041

PATIENT CONSENT FORM

Please initial box

1. I confirm that I have read and understand the information sheet dated 25/06/2020 (Version 3.0) for the above study and have had the opportunity to ask questions which have been answered fully.

2. I understand that my participation is voluntary and that I am free to leave the study at any time without my medical care or legal rights being affected.

3. I understand that relevant sections of my medical records may be looked at by authorised individuals from the research team, from regulatory bodies, from the study Sponsor, or from the NHS Trust in order to check that the study is being carried out correctly. I give permission, provided that strict confidentiality is maintained, for these bodies to have access to my medical records for the above study.

4. I understand that my mobile phone number and email address will be stored until the end of the study securely by the University of Edinburgh and used to send weekly text message reminders to you until your participation on the study ends.

5. I understand that my pseudonymised data will be transferred to the University Of Granada for the analysis.

6. I agree to my data being entered onto a secure database held at the University of Edinburgh, in accordance with the Data Protection Act 2018.

7. I agree to my GP, or any other doctor treating me, being notified of my participation in this study. I agree to my GP being involved in the study, including any necessary exchange of information about me between my GP and the research team.
8. If during the study my clinical care team determine that I have lost capacity to provide informed consent, I will be withdrawn from the study and any identifiable data collected with consent would be retained and used in the study.

9. I agree to take part in the CHAPS study.

Optional consent section (please initial the appropriate box)

10. I give/do not give consent for information collected about me to be used to support other research in the future, including those outside of the EEA.

   Give consent ☐  Do not give consent ☐

11. I give/do not give consent for my data may be linked with appropriate national databases, including Hospital Episode Statistics (HES), and the National Vascular Database as well as for longer term follow-up in the event the trial is extended.

   Give consent ☐  Do not give consent ☐

12. I give/do not give consent to be contacted in the future with regards to this study, should the study be extended.

   Give consent ☐  Do not give consent ☐

Full Name of Participant ___________________________ Date ___________ Signature ___________________________

Name of Person Taking Consent ___________________________ Date ___________ Signature ___________________________

(1 copy for participant; 1 copy for the patient’s medical notes, 1 copy for the site file)